Future of toxicology - Mechanisms of toxicity and drug safety: Where do we go from here?

Chemical Research in Toxicology

Volumn 19, Issue 11, 2006, Pages 1393-1401

  Stevens, James L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CREATINE KINASE; FENFLURAMINE; ISOPRENALINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHENTERMINE; SEROTONIN AGONIST; TROPONIN;

AREA UNDER THE CURVE; ASSAY; BLEEDING; BLOOD TOXICITY; CARDIOTOXICITY; DRUG EXPOSURE; DRUG INDUSTRY; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART MUSCLE NECROSIS; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SCREENING; STRUCTURE ACTIVITY RELATION; TECHNOLOGY; TORSADE DES POINTES; TOXICITY TESTING; VALIDATION PROCESS; VALVULAR HEART DISEASE;

DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; RISK FACTORS; TOXICOLOGY;

ANIMALIA;

EID: 33845340506     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx060213n     Document Type: Review

References (58)

1. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002) Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287 (17), 2215-2220.
2. Kola, I., and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3 (8), 711-715.
3. FDA (2004) Innovation and Stagnation: Challenges and opportunities on the critical path to new medical products. http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html.
4. Greaves, P., Williams, A., and Eve, M. (2004) First dose of potential new medicines to humans: How animals help. Nat. Rev. Drug Discovery 3 (3), 226-236.
5. Lipinski, C., and Hopkins, A. (2004) Navigating chemical space for biology and medicine. Nature 432 (7019), 855-861.
6. Dorato, M. A., and Vodicnik, M. J. (2001) The toxicological assessment of pharmaceutical and biotechnology products. In Principles and Methods of Toxicology (Hayes, W. A., Ed.) pp 243-283, Taylor and Francis, Philadelphia.
7. El-Hage, J. (2004) Preclinical and Clinical Safety Assessment for PPAR Agonists. http://www.fda.gov/CDER/present/DIA2004/Elhage.ppt.
8. Ekins, S., Nikolsky, Y., and Nikolskaya, T. (2005) Techniques: Application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26 (4), 202-209.
9. Karin, M., Yamamoto, Y., and Wang. Q. M. (2004) The IKK NF-kappa B system: A treasure trove for drug development. Nat. Rev. Drug Discovery 3 (1), 17-26.
10. O'Neill, L. A. J. (2006) Targeting signal transduction as a strategy to treat inflammatory disease. Nat. Rev. Drug Discovery 5 (7), 549-563.
11. Li, Z. W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M., Johnson, R., and Karin, M. (1999) The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J. Exp. Med. 189 (11), 1839-1845.
12. Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z. W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., and Karin, M. (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11 (2), 191-198.
13. Sasseville, V. G., Lane, J. H., Kadambi, V. J., Bouchard, P., Lee, F. W., Balani, S. K., Miwa, G. T., Smith, P. F., and Alden, C. L. (2004) Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem.-Biol. Interact. 150 (1), 9-25.
14. Dorato, M. A., and Engelhardt, J. A. (2005) The no-observed-adverse- effect-level in drug safety evaluations: Use, issues, and definition(s). Regul. Toxicol. Pharmacol. 42 (3), 265-274.
15. Wilke, R. A., Reif, D. M., and Moore, J. H. (2005) Combinatorial pharmacogenetics. Nat. Rev. Drug Discovery 4 (11), 911-918.
16. Halford, J. C. (2006) Obesity drugs in clinical development. Curr. Opin. Invest. Drugs 7 (4), 312-318.
17. Gardin, J. M., Schumacher, D., Constantine, G., Davis, K. D., Leung, C., and Reid, C. L. (2000) Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. J. Am. Med. Assoc. 283 (13), 1703-1709.
18. Mekontso-Dessap, A., Brouri, F., Pascal, O., Lechat, P., Hanoun, N., Lanfumey, L., Seif, I., Haiem-Sigaux, N., Kirsch, M., Hamon, M., Adnot, S., and Eddahibi, S. (2006) Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113 (1), 81-89.
19. FDA (2005) Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, http://www.fda.gov/CDER/ guidance/5541fnl.doc.
20. Mutlib, A. E., Gerson, R. J., Meunier, P. C., Haley, P. J., Chen, H., Gan, L. S., Davies, M. H., Gemzik, B., Christ, D. D., Krahn, D. F., Markwalder, J. A., Seitz, S. P., Robertson, R. T., and Miwa, G. T. (2000) The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol. Appl. Pharmacol. 169(1), 102-113.
21. Lazarou, J., Pomeranz, B. H., and Corey, P. N. (1998) Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. J. Am. Med. Assoc. 279 (15), 1200-1205.
22. Uetrecht, J. P. (1997) Current trends in drug-induced autoimmunity. Toxicology 119 (1), 37-43.
23. Law, M., and Rudnicka, A. R. (2006) Statin safety: A systematic review. Am. J. Cardiol. 97 (8A), 52C-60C.
24. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van, D. K., Smith, P., Berger, B., and Heller, A. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32(1), 56-67.
25. Fostel, J., Choi, D., Zwickl, C., Morrison, N., Rashid, A., Hasan, A., Bao, W., Richard, A., Tong, W., Bushel, P. R., Brown, R., Bruno, M., Cunningham, M. L., Dix, D., Eastin, W., Frade, C., Garcia, A., Heinloth, A., Irwin, R., Madenspacher, J., Merrick, B. A., Papoian, T., Paules, R., Rocca-Serra, P., Sansone, A. S., Stevens, J., Tomer, K., Yang, C., and Waters, M. (2005) Chemical effects in biological systems - data dictionary (CEBS-DD): A compendium of terms for the capture and integration of biological study design description, conventional phenotypes, and 'omics data. Toxicol. Sci. 88 (2), 585-601.
26. Yang, C., Benz, R. D., and Cheeseman, M. A. (2006) Landscape of current toxicity databases and database standards. Curr. Opin. Drug Discovery Dev. 9(1), 124-133.
27. Eddy, S. R. (2004) What is Bayesian statistics? Nat. Biotechnol. 22 (9), 1177-1178.
28. Waters, M. D., and Fostel, J. M. (2004) Toxicogenomics and systems toxicology: Aims and prospects. Nat. Rev. Genet. 5 (12), 936-948.
29. Contrera, J. F., Maclaughlin, P., Hall, L. H., and Kier, L. B. (2005) QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr. Drug Discovery Technol. 2 (2), 55-67.
30. Mayne, J. T., Ku, W. W., and Kennedy, S. P. (2006) Informed toxicity assessment in drug discovery: Systems-based toxicology. Curr. Opin. Drug Discovery Dev. 9(1), 75-83.
31. Wilson, A. G., White, A. C., and Mueller, R. A. (2003) Role of predictive metabolism and toxicity modeling in drug discovery - A summary of some recent advancements. Curr. Opin. Drug Discovery Dev. 6(1), 123-128.
32. Lawrence, C. L., Pollard, C. E., Hammond, T. G., and Valentin, J. P. (2005) Nonclinical proarrhythmia models: Predicting Torsades de Pointes. J. Pharmacol. Toxicol. Methods 52 (1), 46-59.
33. Chiang, A. Y., Holdsworth, D. L., and Leishman, D. J. (2006) A one-step approach to the analysis of the QT interval in conscious telemetrized dogs. J. Pharmacol. Toxicol. Methods 54 (2), 183-188.
34. O'Brien, P. J., and Siraki, A. G. (2005) Accelerated cytotoxicity mechanism screening using drug metabolising enzyme modulators. Curr. Drug Metab. 6 (2), 101-109.
35. Sivaraman, A., Leach, J. K., Townsend, S., Iida, T., Hogan, B. J., Stolz, D. B., Fry, R., Samson, L. D., Tannenbaum, S. R., and Griffith, L. G. (2005) A microscale in vitro physiological model of the liver: Predictive screens for drug metabolism and enzyme induction. Curr. Drug Metab. 6 (6), 569-591.
36. Vickers, A. E., and Fisher, R. L. (2005) Precision-cut organ slices to investigate target organ injury. Exp. Opin. Drug Metab. Toxicol. 1 (4), 687-699.
37. Orrenius, S., and Zhivotovsky, B. (2006) The future of toxicologydoes it matter how cells die? Chem. Res. Toxicol. 19 (6), 729-733.
38. Zon, L. I., and Peterson, R. T. (2005) In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discovery 4 (1), 35-44.
39. Driscoll, M., and Gerstbrein, B. (2003) Dying for a cause: Invertebrate genetics takes on human neurodegeneration. Nat. Rev. Genet. 4 (3), 181-194.
40. Song, M. O., Fort, D. J., McLaughlin, D. L., Rogers, R. L., Thomas, J. H., Buzzard, B. O., Noll, A. M., and Myers, N. K. (2003) Evaluation of Xenopus tropicalis as an alternative test organism for frog embryo teratogenesis assay - Xenopus (FETAX). Drug Chem. Toxicol. 26 (3), 177-189.
41. Chaudhary, K. W., Barrezueta, N. X., Bauchmann, M. B., Milici, A. J., Beckius, G., Stedman, D. B., Hambor, J. E., Blake, W. L., McNeish, J. D., Bahinski, A., and Cezar, G. G. (2006) Embryonic stem cells in predictive cardiotoxicity: Laser capture microscopy enables assay development. Toxicol. Sci. 90 (1), 149-158.
42. Baker, T. K., Carfagna, M. A., Gao, H., Dow, E. R., Li, Q., Searfoss, G. H., and Ryan, T. P. (2001) Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem. Res. Toxicol. 14 (9), 1218-1231.
43. Waring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M., Gagne, G., Fagerland, J. A., and Ulrich, R. G. (2003) Isolated human hepatocytes in culture display markedly different gene expression patterns depending on attachment status. Toxicol. in Vitro 17 (5-6), 693-701.
44. Boess, F., Kamber, M., Romer, S., Gasser, R., Muller, D., Albertini, S., and Suter, L. (2003) Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: Possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73 (2), 386-402.
45. Fielden, M. R., and Kolaja, K. L. (2006) The state-of-the-art in predictive toxicogenomics. Curr. Opin. Drug Discovery Dev. 9(1), 84-91.
46. Flaim. C. J., Chien, S., and Bhatia, S. N. (2005) An extracellular matrix microarray for probing cellular differentiation. Nat. Methods 2 (2), 119-125.
47. Critical Path Opportunities Report (2006) http://www.fda.gov/oc/ initiatives/criticalpath/reports/opp_report.pdf.
48. Sandusky, G. E., Means, J. R., and Todd, G. C. (1990) Comparative cardiovascular toxicity in dogs given inotropic agents by continuous intravenous infusion. Toxicol. Pathol. 18 (2), 268-278.
49. Koop, R. (2005) Combinatorial biomarkers: From early toxicology assays to patient population profiling. Drug Discovery Today 10 (11), 781-788.
50. Hood, L., and Perlmutter, R. M. (2004) The impact of systems approaches on biological problems in drug discovery. Nat. Biotechnol. 22 (10), 1215-1217.
51. Hayes, K. R., and Bradfield, C. A. (2005) Advances in toxicogenomics. Chem. Res. Toxicol. 18 (3), 403-414.
52. Lindon, J. C. H. E. N. J. K. (2006) Metabonomics techniques and applications to pharmaceutical research and development. Pharm. Res. 23 (6), 1075-1088.
53. Fielden, M. R., and Zacharewski, T. R. (2001) Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol. Sci. 60 (1), 6-10.
54. Nicholson, J. K., Holmes, E., Lindon, J. C., and Wilson, I. D. (2004) The challenges of modeling mammalian biocomplexity. Nat. Biotechnol. 22 (10), 1268-1274.
55. Sawada, H., Takami, K., and Asahi, S. (2005) A toxicogenomic approach to drug-induced phospholipidosis: Analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83 (2), 282-292.
56. Baillie, T. A. (2006) Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19 (7), 889-893.
57. Smith, D. A., Johnson, D. E., and Park, B. K. (2006) Editorial overview: Safety of drugs can never be absolute. Curr. Opin. Drug Discovery Dev. 9(1), 26-28.
58. Liebler, D. C. (2006) The poisons within: Application of toxicity mechanisms to fundamental disease processes. Chem. Res. Toxicol. 19(5), 610-613.